vs

Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.

ACV Auctions Inc. is the larger business by last-quarter revenue ($183.6M vs $152.6M, roughly 1.2× CATALYST PHARMACEUTICALS, INC.). On growth, ACV Auctions Inc. posted the faster year-over-year revenue change (15.1% vs 7.6%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $-14.7M). Over the past eight quarters, CATALYST PHARMACEUTICALS, INC.'s revenue compounded faster (24.5% CAGR vs 12.3%).

ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ACVA vs CPRX — Head-to-Head

Bigger by revenue
ACVA
ACVA
1.2× larger
ACVA
$183.6M
$152.6M
CPRX
Growing faster (revenue YoY)
ACVA
ACVA
+7.5% gap
ACVA
15.1%
7.6%
CPRX
More free cash flow
CPRX
CPRX
$59.5M more FCF
CPRX
$44.9M
$-14.7M
ACVA
Faster 2-yr revenue CAGR
CPRX
CPRX
Annualised
CPRX
24.5%
12.3%
ACVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACVA
ACVA
CPRX
CPRX
Revenue
$183.6M
$152.6M
Net Profit
$52.7M
Gross Margin
82.9%
Operating Margin
-9.7%
40.5%
Net Margin
34.5%
Revenue YoY
15.1%
7.6%
Net Profit YoY
-5.8%
EPS (diluted)
$-0.12
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACVA
ACVA
CPRX
CPRX
Q4 25
$183.6M
$152.6M
Q3 25
$199.6M
$148.4M
Q2 25
$193.7M
$146.6M
Q1 25
$182.7M
$141.4M
Q4 24
$159.5M
$141.8M
Q3 24
$171.3M
$128.7M
Q2 24
$160.6M
$122.7M
Q1 24
$145.7M
$98.5M
Net Profit
ACVA
ACVA
CPRX
CPRX
Q4 25
$52.7M
Q3 25
$-24.5M
$52.8M
Q2 25
$-7.3M
$52.1M
Q1 25
$-14.8M
$56.7M
Q4 24
$55.9M
Q3 24
$-16.0M
$43.9M
Q2 24
$-17.1M
$40.8M
Q1 24
$-20.5M
$23.3M
Gross Margin
ACVA
ACVA
CPRX
CPRX
Q4 25
82.9%
Q3 25
84.7%
Q2 25
85.9%
Q1 25
87.3%
Q4 24
84.7%
Q3 24
85.0%
Q2 24
87.4%
Q1 24
87.3%
Operating Margin
ACVA
ACVA
CPRX
CPRX
Q4 25
-9.7%
40.5%
Q3 25
-11.9%
44.7%
Q2 25
-3.7%
45.2%
Q1 25
-7.9%
44.8%
Q4 24
-16.2%
44.3%
Q3 24
-10.0%
39.6%
Q2 24
-11.6%
44.2%
Q1 24
-15.5%
27.5%
Net Margin
ACVA
ACVA
CPRX
CPRX
Q4 25
34.5%
Q3 25
-12.3%
35.6%
Q2 25
-3.8%
35.6%
Q1 25
-8.1%
40.1%
Q4 24
39.4%
Q3 24
-9.4%
34.1%
Q2 24
-10.6%
33.2%
Q1 24
-14.1%
23.6%
EPS (diluted)
ACVA
ACVA
CPRX
CPRX
Q4 25
$-0.12
$0.40
Q3 25
$-0.14
$0.42
Q2 25
$-0.04
$0.41
Q1 25
$-0.09
$0.45
Q4 24
$-0.15
$0.44
Q3 24
$-0.10
$0.35
Q2 24
$-0.10
$0.33
Q1 24
$-0.13
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACVA
ACVA
CPRX
CPRX
Cash + ST InvestmentsLiquidity on hand
$271.5M
$709.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$429.7M
$954.3M
Total Assets
$1.1B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACVA
ACVA
CPRX
CPRX
Q4 25
$271.5M
$709.2M
Q3 25
$265.3M
$689.9M
Q2 25
$258.4M
$652.8M
Q1 25
$291.9M
$580.7M
Q4 24
$224.1M
$517.6M
Q3 24
$252.5M
$442.3M
Q2 24
$215.0M
$375.7M
Q1 24
$209.8M
$310.4M
Stockholders' Equity
ACVA
ACVA
CPRX
CPRX
Q4 25
$429.7M
$954.3M
Q3 25
$434.4M
$920.2M
Q2 25
$448.8M
$856.0M
Q1 25
$439.6M
$794.3M
Q4 24
$440.0M
$727.6M
Q3 24
$456.2M
$660.9M
Q2 24
$457.6M
$608.7M
Q1 24
$458.3M
$561.4M
Total Assets
ACVA
ACVA
CPRX
CPRX
Q4 25
$1.1B
$1.1B
Q3 25
$1.2B
$1.1B
Q2 25
$1.1B
$971.9M
Q1 25
$1.2B
$908.9M
Q4 24
$984.1M
$851.4M
Q3 24
$1.0B
$772.0M
Q2 24
$1.0B
$706.4M
Q1 24
$1.0B
$646.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACVA
ACVA
CPRX
CPRX
Operating Cash FlowLast quarter
$-12.4M
$44.9M
Free Cash FlowOCF − Capex
$-14.7M
$44.9M
FCF MarginFCF / Revenue
-8.0%
29.4%
Capex IntensityCapex / Revenue
1.2%
0.0%
Cash ConversionOCF / Net Profit
0.85×
TTM Free Cash FlowTrailing 4 quarters
$69.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACVA
ACVA
CPRX
CPRX
Q4 25
$-12.4M
$44.9M
Q3 25
$10.3M
$32.4M
Q2 25
$13.7M
$71.3M
Q1 25
$66.6M
$60.0M
Q4 24
$-3.2M
$70.9M
Q3 24
$21.1M
$72.9M
Q2 24
$4.5M
$64.1M
Q1 24
$43.0M
$31.9M
Free Cash Flow
ACVA
ACVA
CPRX
CPRX
Q4 25
$-14.7M
$44.9M
Q3 25
$7.7M
Q2 25
$10.9M
$71.3M
Q1 25
$65.3M
Q4 24
$-3.9M
$70.8M
Q3 24
$20.2M
$72.6M
Q2 24
$2.7M
$64.1M
Q1 24
$41.9M
$31.7M
FCF Margin
ACVA
ACVA
CPRX
CPRX
Q4 25
-8.0%
29.4%
Q3 25
3.8%
Q2 25
5.6%
48.6%
Q1 25
35.7%
Q4 24
-2.5%
49.9%
Q3 24
11.8%
56.4%
Q2 24
1.7%
52.3%
Q1 24
28.8%
32.2%
Capex Intensity
ACVA
ACVA
CPRX
CPRX
Q4 25
1.2%
0.0%
Q3 25
1.3%
0.0%
Q2 25
1.5%
0.0%
Q1 25
0.7%
0.0%
Q4 24
0.4%
0.1%
Q3 24
0.6%
0.2%
Q2 24
1.1%
0.0%
Q1 24
0.7%
0.2%
Cash Conversion
ACVA
ACVA
CPRX
CPRX
Q4 25
0.85×
Q3 25
0.61×
Q2 25
1.37×
Q1 25
1.06×
Q4 24
1.27×
Q3 24
1.66×
Q2 24
1.57×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACVA
ACVA

Auction Marketplace Revenue$77.6M42%
Other Marketplace Revenue$72.4M39%
Customer Assurance$24.1M13%
Data Services Revenue$9.4M5%

CPRX
CPRX

Firdapse$97.6M64%
Agamree$35.3M23%
Fycompa$19.6M13%

Related Comparisons